In the digital age, a genetics cohort has become much more than a simple means of determining the cause of a disease. Two-sided markets, of which 23andMe, Ancestry DNA and MyHeritage are the best known, have showed this perfectly over the last few years: a cohort has become a means of producing massive amounts of data for medical, scientific and commercial exploitation, and for genetic use in particular. French law does not currently allow these foreign private companies to develop on French national territory and also forbids the creation of similar entities in France. However, at least in theory, this same law does not preclude the creation of new types of cohorts in France inspired by the success of two-sided markets but retaining features specific to the French healthcare management system. We propose an optimal solution for France, for genomic studies associated with multi-subject questionnaires, still purely theoretical for the moment: the development, with no need for any change in the law, of France's own version of "Genetics
| BACKGROUND
French genetic research still has a relatively "classical," if not archaic view of the nature of a cohort. 1 As highlighted by a recent expert opinion from the French national consultative committee for ethics (CCNE),* apart from being rather small, French cohorts are subject to a number of other problems: data dispersion, gaps in interoperability and insufficient sharing and coordination of resources. Two national platforms are being set up to deal with these difficulties: the French national plan for genetic data, MFG-2025 (Plan France Médecine Génomique 2025 † ) and the Health data hub. ‡ However, the real effectiveness of these platforms remains, at this stage highly relative. The problem is mostly due to the organization and functioning of cohorts in France.
Typically, a cohort is defined as a means of studying the health of different individuals over time. In this framework, we talk about cohorts of patients or of individuals from the general population, but cohort studies have historically had a restricted scope in any case. However, the new two-sided markets, [2] [3] [4] such as 23andMe, § Ancestry DNA** and MyHeritage, † † have clearly showed that, in the digital era, in genetics, limiting the scope of research has become a scientific and economic limitation. Indeed, there is a clear advantage to studying everything possible in the general population, without prior assumptions, to identify genetic features more easily and, often, serendipitously.
These two-sided markets have created new cohorts designed neither to identify the cause nor determine the natural course of a specific disease. Their purpose is to generate massive amounts of data, including genetic data in particular, that can be transformed into different types of information, some useful and others suitable for valorization. 4, 5 These cohorts have been restructured and reorganized so as to function as an industrial means of producing data and information relating to genetics, connected or unconnected to health. It is clear that this new cohort model has proved itself both scientifically and economically. 6, 7 23andMe illustrates this perfectly, with its cohort of several million individuals, with and without particular diseases. Thus, even though these private companies are banned in France, they have already published dozens of scientific publications and have a capital of several billion dollars, 8 amassed in less than 15 years.
Whether we like it or not, this success, however, debatable, raises questions about the efficacy of current French cohorts, for genetics studies at least. 1 In the face of the results of 23andMe, current French cohorts appear to be obsolete and in need of profound reorganization to render them more effective and more competitive globally. France now has only two options. The first is to change the law, which, in theory, prohibits these two-sided markets from developing in France, and, in practice, prevents similar entities from being created in France. ‡ ‡ However, this choice entails a risk of offering these already established two-sided markets a monopoly on our soil, given the huge lead they already have over any French competition. The second option is to leave the law unchanged and to create cohorts inspired by these two-sided markets, but with beneficial characteristics more compatible with the current French system. 9, 10 Like these two-sided markets, these cohorts would be multithemed, with dynamic consent and virtual questionnaires completed with the use of new information and communication technologies, to allow participant autonomy and to make it possible to develop different research themes over time, from cancers to physical or behavioral traits, for example, if desired. However, these cohorts would not be two-sided markets, but would correspond to a specific research protocol ("recherche impliquant la personne humaine (RIPH)" § § in French, or research involving humans).
The goal of this RIPH would be genomic studies associated with multi-subject questionnaires. This would initially make it possible to determine the genetic factors easiest to identify (ie, monogenic factors) without prior assumptions, because an infinite number of questions could be posed. This would accelerate genome mapping and the discovery of more complex (ie, polygenic) genetic factors.
Within the framework of an RIPH, participation would be free and would be supported by a public or private academic structure (hospital, institute, university etc.). Unlike two-sided markets, they would receive data of a uniformly high quality (ancestry and true scientifically validated predispositions) and any medical predispositions detected would be managed free-of-charge by the French national health insurance system, which is accessible to all. In these conditions, French participants, who generally trust the French state to ensure the security of their personal data, might prefer these RIPHs over foreign two-sided markets. This is the only solution that would enable France to deal effectively with these two-sided markets and their genetic tests, which are otherwise destined to spread throughout France, with or without legal restrictions. We present here an optimal solution, which we have called e-CohortE (e-CE), providing an overview of its organization and global functioning.
| e-CohortE
In this system, recruitment begins with the presentation, on a digital support, of the information notice, followed by the signing of the electronic consent form by the participant during a consultation with one of the investigating doctors for the protocol. The information notice would, of course, explain the ultimate aim: "genomic studies associated with multi-subject questionnaires." This consent is, therefore, virtual ( Figure 1A ). 11 It is established between the participant (who may or may not be a patient) and the investigating doctor, via a computer, a computer tablet, or a smartphone. The investigating doctor reads and explains aloud the entire content of the information notice and the virtual consent form to the participant, in accordance with French law, before obtaining the informed consent of the participant.
The information notice should be as explicit as possible, and the investigating doctor must be present when the participant signs the electronic consent form. The participants then belong to the cohort for a research protocol in human genetics and may, if they wish, obtain a printed version of their consent and the information notice.
Following signature of the consent form, an observation notebook, also in electronic form, is completed by the investigating doctor, together with the entry questionnaire. This entry questionnaire contains a short set of original questions common to the entire cohort. Of course, investigating doctors, given their specialty or interest, can choose to ask the participant additional validated questions.
When giving express consent, the participant may, of course, authorize access to his or her shared medical dossier (DMP, for "dossier médical partagé" in French),*** which, depending on the structure, may contain an authorization to access the national health data system (système national des données de santé, SNDS), † † † itself consisting of the national information system for the various regimes of the national health insurance system (système national d'Information inter-régimes de l'Assurance maladie, SNIIRAM) ‡ ‡ ‡ ; data from hospitals and other healthcare establishments (under the program for the medicalization of information systems-programmede médicalisation des systèmes d'Information, PMSI § § § ); statistical data for causes of death (Basede données sure les Causes Médicales de Décès en France, BCMD)**** and, in the near future, data relating to disabled individuals.
The participants may answer all or only some of the questions, in the knowledge that they do not need to justify the absence of a response to a particular question and that this absence will not invalidate research relating to other questions that they have answered. The participants may, either at home or elsewhere, at any time, answer the other questions to which they did not respond at the time of recruitment or that the doctor did not necessarily ask them, given his or her specialty. This situation is made possible by the electronic nature of the research protocol and the availability of new information and communication technologies.
At the end of this first consultation, the participants receive an identifier (a "login" name) and a password, with all the necessary security precautions, to allow them to connect to the study website via the Internet on a computer or via a smartphone application. Thus, wherever they happen to be, the participants can access their personalized secure accounts, in which they can find their consent forms, information notices 
Information (3) (ancestry results)
F I G U R E 3 Modeling of interactions between participants, doctors and researchers (2) . The genetic data obtained from a genomics platform are analyzed and combined with the responses to the questionnaires present in the database via a computer platform, which returns the data directly to the participant without passing by the doctor. The data delivered are the overall results of the research (information (1)). Some information relating to the health of the participant (information (2)) may also be returned to the participant, if the participant so wishes. However, this information is subject to prior expert evaluation and validation by an accredited geneticist and a multidisciplinary committee before its transmission to the doctor and then to the participant during a consultation. Other information relating to the ancestry of the participant may be delivered directly to the participant online (information (3) 
| Perspectives
Once the cohort (biobank, database) and its network of participants, doctors, investigators, researchers and coordinators have been consti- e-CE will not close its doors to pharmaceutical and biotech companies. This will also differentiate it from certain public cohort protocols clearly stipulating that no sharing or exchange of data with the private sector is permitted. A private company (pharmaceutical or biotech company) can, therefore, pose "its" question to "our" cohort, in the same manner as an academic laboratory (again, subject to consent and to the maintenance of participant confidentiality, thanks to the traceability of questions) ( Figure 6 ). The participant sees simply that the question comes Furthermore, thanks to the use of dynamic consent, [12] [13] [14] [15] [16] [17] if other sponsors develop a study based on a model similar to ours, they will be able to offer their participants the chance to collaborate with other cohorts for one or several questionnaires. Thus, even in the case of a single-topic e-CE, it remains of interest for both the participants and the sponsor to engage in such dynamic research. It is possible to collaborate just for one or several questionnaires, to increase independently the sizes of the different cohorts and/or even to fuse them, subject to the consent of the participants, to constitute a participatory Informatics Genomics @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ € Biobank @ € € Database F I G U R E 7 Modeling of interactions between participants, doctors and researchers plus external researchers and companies. In the case of collaboration in an interventional study with a private or public sector partner, or of a collaboration between public and private sector partners, the participants of the cohort with profiles corresponding to that sought are contacted via the computer interface. The participants are free to participate in this new study, by signing a new consent form independent of that for the main protocol. Thus, e-CE makes it possible to obtain information or to investigate the possibility of recruitment for other studies and for other sponsors [Colour figure can be viewed at wileyonlinelibrary.com] "megacohort" (Figure 8 Although purely theoretical at this stage, e-CE respects not only French law, but also the new European general data protection rules (GDPR) ‡ ‡ ‡ ‡ and follows the recent report on artificial intelligence from the French parliamentarian Cédric Villani, § § § § and that of the French national ethics consultative committee (CCNE)***** concerning the production, usage, and ownership of personal data, particularly those of a genetic nature. The aspect of the ownership of genetic data deserves and will receive, much closer consideration, to improve the scientific and economic valorization of these data. 18 In addition, e-CE also respects the notion of developing a single identical protocol for genetic studies that in reality deal with multiple themes, rather than multiple protocols for single-theme studies supported by a data warehouse (as currently recommended by the French data protection agency, the CNIL).
With such an organization and mode of functioning, e-CE will facilitate the scientific use of genetic data in France, whilst respecting French and European laws and regulations. e-CE will make it possible to perform research projects in human genetics more effectively and rapidly in France, whilst offering participants the possibility of direct, responsible and conscious involvement, validating the protocol de facto through this link of confidence.
| Important issues and conclusion
In practice, of course, various issues of different natures must be taken into account for the effective implementation of such a system. First and foremost, there is a major scientific issue: improving the mapping of the human genome. It has become indispensable, to address this issue, to make it possible for all types of genetics studies authorized by the law to be performed within the same research protocol, rather than through data warehouses. Indeed, the use of a data warehouse in France requires the submission of a protocol to obtain authorization to study some of the data present in the warehouse, and this wastes time that could be more usefully spent on the protocol. e-CE addresses this problem specifically. Rather than having to come up with a new research protocol with a specific theme and cohort each time, e-CE makes it possible to study, within the same cohort, diverse topics, ranging from type 2 diabetes to face shape, for example. All this is important because, in the world of data, nothing @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ P1 Prior information, via an advertisement, in parallel with a doctor dedicated to this process, would solve this problem. In any case, at this stage, the many technical means required will require relatively high levels of funding, most of which will need to be found by the protocol.
P2
However, we should not forget that a cohort of 10 million participants (ie, 23&Me) is currently considered to be worth 2 billion dollars, automatically leading to investment. Thus, in addition to possible public funding, the various partnerships envisaged with private companies should make it possible to cover these costs ( Figures 5-6 and 7) and, at the same time and in the same space, the development of e-CE. Along the same lines, e-CE does not rule out financial and scientific collaboration with foreign two-sided markets, within the constraints of European and French standards. In this case, France would retain control over French genetic data, again with the express consent of the participants.
Furthemore, we believe that the generalization of e-CE would maintain and increase the quality of care without overloading the health system, because e-CE is simply a way of optimizing current and future RIPHs within our health system. Furthermore, in the generalization of e-CE, to prevent the cohort becoming enriched in disease-prone individuals, we recommend the enrollment of all the individuals accompanying the patients, their helpers or spouses in the studies. This should make it possible to obtain cohorts including reasonably healthy people with a better distribution of ancestries and genealogies.
In addition to these scientific, technical, financial and economic issues, we must consider another set of issues that is just as important: ethical issues. Indeed, France appears to be opting for the continuation of a restrictive legal and moral framework concerning the production and use of genetic data. † † † † † This is not necessarily a bad choice in itself, as it makes it possible to prevent two-sided markets from obtaining a monopoly on the production of genetic data in France. 9 However, the law is not applied strictly, forcing researchers who wish to work on large cohorts to supply their questionnaires free-of-charge in return for a tiny amount of data, whilst these companies have direct access to the DNA of these participants. It is for this reason that such a protocol must be managed. e-CE will meet this need by having a scientific and ethics committee composed of doctors, biologists, philosophers, bioethicists, legal experts, sociologists and economists, who will evaluate the pertinence and necessity of the various amendments, new questions or additions of new investigating centers proposed to the ethics committee (CPP) and/or the CNIL. This committee will also select the research teams receiving funding and will take decisions concerning the delivery of research results within the cohort.
Another important issue is control over French data, to prevent an information drain and to ensure that we can learn to analyze these data en masse. Indeed, it is sad that the report on the revision of French bioethics law (N1572), which anticipates the massive arrival of these illegal and often medically false or incomplete genetic tests in France, recommends costly solutions that would be dangerous for our healthcare system. Indeed, this report proposes increasing the number of genetic counselors to analyze these poor-quality results, to reassure those who have illegally had such tests performed. Now, if, through the e-CE system, we were to deliver high-quality information directly to the French people within RIPHs, there would no longer be any advantage to resorting to these companies, some of which charge for their services and do not respect the GDPR, because a medically validated predisposition identified by e-CE would lead to free healthcare in France. However, it should be borne in mind that in France, as in other European countries, genetic discrimination is strictly prohibited, whereas the United States allows a number of exceptions to this rule.
Thus, the major ethical issues relating to what essentially amounts to the industrialization of genetic data production include, in particular, the issue of who owns the data. Indeed, over the course of a few decades, we have passed from the local and artisanal production of genetic data to a worldwide and standardized system of data production. This industrialization has made it possible to increase the amount of genetic data generated and to increase production quality, but it has also led to genetic data being seen as commercial goods. In the eyes of French law, genetic data are considered to be an element of the human body that belongs to the donor and not an asset belonging to an owner (French Civil Code Article 16-1). In other words, in France, our bodies and genetic data are considered to belong to us, but we do not own them. They are not considered to be a commodity, and certainly not a commercial one. The problem in France is therefore as follows: How can we correctly industrialize the production of genetic data, to remain competitive, if only scientifically, without considering genetic data as a commodity? The response is as complex as the question, and the implementation of e-CE could help us to find the answer.
In any case, even at this theoretical stage, it is clear that e-CE offers a relatively simple and obvious methodology, with various indirect arguments of different natures in its favor. The MFG-2025 should make use of a single cohort, such as e-CE, rather than multiple small protocols with very restricted goals. However, only a real implementation of this system would make it possible to test its real efficacy, as proposed by the CCNE (expert opinion 129 ****** ), with the testing of genetic information collection from the general population, in particular. e-CE would constitute a real French-style "Genetics version 2.0," † † † † † http://www.assemblee-nationale.fr/15/rap-info/i1572.asp ****** https://www.ccne-ethique.fr/sites/default/files/avis_129_vf.pdf essential for France to remain competitive, both scientifically and economically, in terms of genetic research, in the face of these new foreign two-sided markets, which, every day, extend their influence a little further, thereby creating a continuous drain of our genetic data abroad, to the detriment of France.
